Abstract
Results: No differences in age, sex, disease duration, associated diseases, or anal involvement were observed between the 38 patients treated with PPIs and the 76 control subjects. In the group exposed to PPIs, more patients had ileal involvement and history of prior hospitalization or operation. Concurrent treatment with azathioprine and 5-amino-salicylates was more prevalent in the control group, whereas changes in medication during the 6-month covariate assessment period were significantly more frequent in the group exposed to PPIs. However, after adjusting these confounding factors using multivariate binary logistic regression, the PPI use in the CD patients significantly increased the risk of severe flareup (odds ratio, 6.896; 95% confidence interval, 1.110 42.850) and mild flare-up (odds ratio, 14.658; 95% confidence interval, 3.377 63.628). Conclusions: The use of PPIs to suppress gastric acid secretion may be associated with poor prognosis in CD. Medical practitioners should pay special attention when prescribing gastric acid-suppressing agents for CD patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
